V8 NEXUS

Glyco Liver Profile

NA2

NA3
NA2FB
NGA2F

The next generation in

non-invasive liver diagnostics
INFLAMMATION • FIBROSIS • CIRRHOSIS • HCC
 “ The Glyco Liver Profile is a unique test, not
only capable of defining the degree of liver
fibrosis but also the presence of cirrhosis. In
patients with cirrhosis, the Glyco Liver Profile
is able to predict the chances of primary
Complete picture of chronic
liver disease progression

”
liver cancer development. As such it can
categorise your patient into high or low risk
for this devastating tumour. Classifying liver disease
Professor Hans Van Vlierberghe, Glyco Liver Profile enables

One profile.
Hepatologist at UZ Ghent the stratification of patients
according to a full range of
hepatic categories.

Four disease markers.

Inflammation
Able to detect hepatic
inflammation which drives
fibrosis and cirrhosis.
Can help the hepatologist
differentiate between
steatosis and steatohepatitis.

The Glyco Liver Profile is a unique, non-invasive test that provides the clinician with a Fibrosis
full picture of liver health regardless of aetiology — all from a single blood sample. Clearly defines the level of
liver fibrosis. The Fibrosis
Index provides results in a
METAVIR stage score (F1-F4).
Streamline and reduce costs Stratify patient care Predict and save lives
Cirrhosis
A single kit and serum sample allows you Our intuitive four-index results allows you A proven and accurate prognostic method
to consolidate screening — reducing time, to easily identify and manage patients that provides automated, long-term patient The Cirrhosis Index can detect
life costs and complexity for your clinic, early with a sensitive, specific and assessment for a more complete and the absence or presence
laboratory and patients. comprehensive profile. consistent picture of disease progression. of cirrhosis, discriminating
between compensated and
decompensated forms.

Hepatocellular carcinoma (HCC)

The Glyco Liver Profile is able to detect

1.5 80 26 2
1.5 billion Over 80% of Increase in Liver cancer is
BN overweight or % obese adults % 5-year medical nd the second most patients with chronic liver disease who
obese adults suffer from costs due to common cause of are at high risk of developing HCC
worldwide NAFLD NAFLD/NASH cancer death
within 5 years.
Clinical glycomics offers a direct,
measurable insight into liver health
Provides a complete patient monitoring tool
A single venous blood test offering a cost-effective alternative to expensive biopsy
N-linked Glycan
Glycomics is the study of glycans — polysaccharide
structures found on secreted and membrane Normal Liver Inflammation Fibrosis Cirrhosis HCC
bound glycoproteins. Their main roles include
the maintenance of cell structure, molecular
signalling, protein folding and cell recognition as
well as a host of other functions.

Serum glycoproteins are predominantly

manufactured within hepatocytes, so changes to
the expression of specific circulating N-glycans can
Cell membrane
provide a complete picture of liver health.

■■Normal range cutoff ■■Detect inflammation ■■Determine and stage the ■■Define the presence or ■■Risk assess progression
Electropherogram of N-glycan profile available for simple ■■No interference from levels of fibrosis absence of cirrhosis from cirrhosis to HCC
screening coexisting fibrosis ■■Monitor patient progression ■■Discriminate between ■■Provides a risk for
■■Rule out patients without ■■Discriminate between ■■Provides a holistic image of compensated and progression to HCC in the
inflammation NAFLD and NASH liver fibrosis decompensated cirrhosis next five years

NA2 ê
NA2 ê
NA2 NA2 ê
NA3 NA2 ê
NGA2F NA2FB
é é NA2 é
é é é é é NGA2F NA2FB
NA2FB NA2FB ê NA2FB ê NGA2F NA2FB
ê
NGA2F NGA2F
NGA2F ê
time NA3 NA3 NA3 NA3 NA3

Glycan biomarkers provide four clear, accurate results

Inflammation Index Inflammation Index Inflammation Index Inflammation Index Inflammation Index
The Glyco Liver Profile builds a comprehensive picture of liver damage by
selecting and measuring the four specific N-glycans shown above, and
Fibrosis Index Fibrosis Index Fibrosis Index Fibrosis Index Fibrosis Index
calculating ratios between them to produce four results:
Cirrhosis Index Cirrhosis Index Cirrhosis Index Cirrhosis Index Cirrhosis Index
Inflammation Index Fibrosis Index
Prognostic (HCC) Index Prognostic (HCC) Index Prognostic (HCC) Index Prognostic (HCC) Index Prognostic (HCC) Index

Detects hepatic inflammation, the key Detects and measures fibrotic

driver of hepatocyte damage
Cirrhosis Index
Detects and discriminates between
compensated and decompensated cirrhosis
change (METAVIR F1-F4)
Prognostic (HCC) Index
Defines the risk of HCC
development within five years
Results show normal liver
pathophysiology. Hepatocytes
are uniform in size and
distributed evenly. Lipid content
is less than 10%. No external
drivers of hepatic inflammation
are present, and no direct
damage is apparent.
Excess uptake of lipids
into hepatocyte vacuoles
is typical in NAFLD, driving
steatohepitis. Galactosylation of
immunglobulin bound glycans
is inhibited. When correlated
to hepatocyte regeneration,
inflammation can be identified.
Inflammation facilitates
hepatocyte death. Collagen
replaces tissue that is unable to
regenerate, resulting in fibrosis
around hepatocellular nodules.
Regenerating hepatocytes have
altered enzymic activity resulting
in modified glycan metabolism.
In this example extensive
fibrosis has occurred, altering
the structure of the liver and
impairing function. Vascular
occlusion and bile duct blockage
are common occurrences
resulting in oesophageal varices
and jaundice.
Progression to fibrosis and
cirrhosis can be directly linked
to the five year risk of developing
hepatocellular carcinoma.
Patients can be split into high and
low risk groups by correlating
the cirrhotic N-glycan markers,
NA2FB and NA3.
Rapid and convenient patient
sample analysis with V8 NEXUS
Sample preparation
Proteins are denatured and treated allowing
enzymes to reach glycosylation sites. Specific
enzymes release glycans for analysis, which are
then labelled allowing visualisation.
Capillary electrophoresis
Samples are loaded onto the fully automated
V8 Nexus for separation. CZE is a powerful
analytic technique separating sample
components based upon the difference in
their mass to charge ratio.
Sample results
Resulting electropherograms focus specifically
on four key N-glycans. All information
is detected, measured and compared
automatically using Platinum 5 software.
A complete patient assessment tool on one screen
Patient results
Retrieve, manage and compare multiple
patient result data with a single tap.
Monitoring
This non-invasive test allows for the
patient to be assessed at regular intervals
in order to monitor the disease in
conjunction with treatment strategies.
Patient results can be displayed in a
simple, user-friendly grid view for an
at-a-glance overview of the patient’s
progression and response to treatment.
Liver profile indices
Inflammation
Provides a linear correlation to the
progression of disease and can
distinguish between NAFLD and NASH.
Fibrosis
The Fibrosis Index provides details
on the level of fibrosis and correlates
to staging scores defined by the
METAVIR system.
Cirrhosis
Results will determine the presence of
cirrhosis and differentiates between
compensated and decompensated forms.
HCC Risk
The software will additionally provide
a prognostic risk indication for the
development of hepatocellular carcinoma.
Demographics
Connects to your laboratory LIS for
a fully integrated workflow.
Complementary information
The software uses existing data and demographics from within its database together with additional data from
the laboratory’s information management systems to calculate scores such as NAFLD, BARD and FIB-4.
“
”
Glycomics-based biomarkers are a new tool for clinicians. The Glyco Liver Profile provides a
reliable marker for early diagnosis of cirrhosis and for risk stratification of hepatocellular carcinoma
development. These are essential tools for the development of personalised medicine.

Doctor Xavier Verhelst, Hepatologist at UZ Ghent

The Glyco Liver Profile is available

at hundreds of labs worldwide.
V8 NEXUS Tests:

Serum Proteins

V8 NEXUS: a versatile, multi-analyte platform Urine Proteins

Glyco Liver Profile is the newest addition to Helena Biosciences’ V8 Immunodisplacement

NEXUS analytical portfolio. With a widely established global install
base, V8 NEXUS provides clinicians with a broad menu of clinical tests Haemoglobin
for blood sciences laboratories. UltraScreen

High-throughput non-invasive liver test Haemoglobin A1c

V8 NEXUS delivers the high performance automation required for a Haemoglobin IEF
dedicated liver testing laboratory. With intuitive touchscreen software
and simple connectivity to laboratory systems, it is the ideal platform CDT
for a low-cost, efficient workflow.
Glyco Liver Profile
Learn more about clinical glycomics
Chronic Kidney
Our Glyco Liver Profile website is continually updated with new Disease
information and educational material relating to clinical glycomics,
including videos, research papers and more.

Helena Biosciences Europe Tel +44 (0)191 482 8440

Queensway South, Team Valley Trading Estate, Fax +44 (0)191 482 8442
Gateshead, Tyne and Wear, NE11 0SD, United Kingdom sales@helena-biosciences.com

© 2018 Helena Biosciences. All rights reserved. HL-2-3406P 2018/03 (1)

www.helena-biosciences.com/glp